Neurocrine Biosciences (NBIX) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Catalyst-Rich 6 Months Ahead for Neurocrine Bio. (NBIX), Cowen Notes
July 30, 2015 9:53 AM EDTCowen analyst Phil Nadeau reiterated an Outperform rating and boosted his price target on Neurocrine Bio. (NASDAQ: NBIX) to $55.00 (from $45.00), saying the company is gearing up for a catalyst-rich 6 months.
Nadeau commented, "NBIX's pipeline should yield a number of catalysts over the next 6... More
